Kangfang bio-anti-PD-1 monoclonal antibody registration reaches the primary end point of the third-line treatment of nasopharyngeal carcinoma

On October 12, Kangfang Bio and China Biopharmaceuticals jointly announced that the anti-PD-1 monoantigen Pai Ampri (Anico, developed code-named AK105) for third-line therapeutic metastatic nasopharyngeal cancer (NPC) registered clinical studies, reached the main endpoint of objective mitigation rate (ORR) assessed by independent imaging.
Pai Ampri monoantosis demonstrated good clinical efficacy and safety in NPC patients who had been treated with multiple lines in the past.
, according to a press release, Kangfang Bio intends to communicate with China's State Drug Administration (NMPA) in the near future before applying for the new drug to be marketed.
public information shows that the Fc-mediated and complement-mediated erration functions of the candidate drug Pai Ampley are completely removed by mutations in the Fc region, and have the characteristics of slow antigen binding and dissocation rate.
these characteristics make Pianpre more effective in blocking PD-1 pathfour activity and maintaining stronger T-cell anti-tumor activity, potentially becoming a better clinically-advantaged anti-PD-1 drug.
May, the NDA used by Paianpree to treat at least a second-line system chemotherapy relapse or recurring (r/r) classic Hodgkin's lymphoma (r/r cHL) was accepted by the NMPA.
Pai Anpley Single Resistance was jointly developed and commercialized by a joint venture established by Kangfang Bio and Zhengda Tianqing, a subsidiary of China Biopharmaceuticals.
According to the press release, Pianpri is the only new drug available for the development of single or combination therapies based on PD-1 antibodies in China, and is one of the candidates for PD-1 monoclonal antibodys in the late stages of clinical development, differentiated and possibly best-in-class.
According to the Drug Clinical Trial Registration and Information Disclosure Platform, Pampley is currently conducting a number of clinical trials involving a variety of cancers including liver, stomach, lung, classic Hodgkin's lymphoma, and advanced head and neck chest tumors.
.